**Name of Journal: *World Journal of Otorhinolaryngology***

**ESPS Manuscript NO: 21622**

**Manuscript Type: Review**

**It is 2015: What are the best diagnostic and treatment options for Ménière’s disease?**

Shah S *et al.* Diagnostic and treatment options for Meniere’s disease

**Safeer Shah, Abel Ignatius, Syed Ahsan**

**Safeer Shah, Abel Ignatius**, Wayne State University School of Medicine, Detroit, MI 48201, United States

**Syed Ahsan**, Department of Otolaryngology/Head and Neck Surgery, Henry Ford Health Systems, Detroit, MI 48202, United States

**Author contributions**: Shah S was involved in the acquisition of information, drafting the article and final approval of the version of the article for submission;

Ignatius A was involved in the acquisition of information, drafting of the article and approval of the final version for submission; Ahsan A was responsible for conception and design of the review, drafting the article, performing final editing and approval of the final version for submission.

**Conflict-of-interest** **statement:** The authors have no conflicts of interest to declare.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Syed Ahsan MD, FACS,** Department of Otolaryngology/Head and Neck Surgery**,** Henry Ford Health System,2799 W. Grand Blvd. K-8, Detroit, MI 48202, United States. sahsan3@hfhs.org

**Telephone:** +1-313-9167442

**Received:** July 22, 2015

**Peer-review started:** July 27, 2015

**First decision:** October 13, 2015

**Revised:** October 22, 2015

**Accepted:** December 7, 2015

**Article in press:**

**Published online:**

**Abstract**

Ménière’s disease (MD) is a common cause of recurrent vertigo. Its pathophysiology is still unclear and controversial. The most common histological finding in postmortem temporal bone studies of patients is endolymphatic hydrops (EH). However, not all cases of hydrops are associated with MD and it may represent the end point of various etiologies. The diagnostic criteria for MD have undergone changes during the past few decades. A recent collaboration among specialty societies in United States, Europe and Japan has given rise to a new set of guidelines for the diagnosis and classification of MD. The aim is to develop international consensus criteria for MD that would help improve the quality of data collected from patients. The diagnosis of MD can be difficult in some cases as there is no gold standard for testing. Previous use of audiometric data and electrocochleography are poorly sensitive as screening tools. Recently magnetic resonance imaging as a diagnostic tool for identifying EH has gained popularity in Asia and Europe. Vestibular evoked myogenic potentials are also used but lack specificity. Finally, the treatment for MD has improved with the introduction of intratympanic treatments with steroids and gentamicin as well as less invasive treatment with the Meniett device.

**Key words:** Meniere’s disease; Review; Pathophysiology; Diagnosis; Treatment

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The pathophysiology of Ménière's disease is still unclear and controversial. The most common histological finding in postmortem temporal bone studies of patients is endolymphatic hydrops. This finding is utilized in the newest method of diagnosis using MRI with intratympanic or *iv* gadolinium. Changes to the diagnostic criteria have been proposed with collaboration from various international societies. This will help in communication and improve quality of published data. Finally, the use of intratympanic steroids and Meniett pressure treatments offers less invasive and destructive treatments for patients with Meniere’s disease.

Shah S, Ignatius A, Ahsan S. It is 2015: What are the best diagnostic and treatment options for Ménière’s disease? *World J Otorhinolaryngol* 2015; In press

**INTRODUCTION**

Ménière’s Disease (MD) is an inner ear disorder that is characterized by episodic vertigo, low-pitched tinnitus and fluctuating hearing loss lasting for a minimum of 20 min. In the United States, 190 people per 100000 are affected, with a 2:1 female to male ratio[1]. MD was named after the French physician Prosper Ménière, who in 1861 first argued that MD was an inner ear disorder and not a neurological one[2]. Much time after his death, the most common finding in postmortem human temporal bone studies of MD patients was endolymphatic hydrops (EH), which is the dilation of the membranous labyrinth of the inner ear[3]. It should be noted however that not all cases of EH are associated with MD[4].The lack of certainty in understanding the pathophysiology of MD makes it difficult to properly diagnose and treat. Most treatments are aimed at reducing endolymphatic size and pressure after which non-responders go on to ablative treatments.

**PATHOPHYSIOLOGY**

MD is an idiopathic disorder wherein the mechanism underlying its pathophysiology is still unclear and controversial. Affected individuals differ in terms of etiology and thus many studies propose various explanations for the manifestation of symptoms. However, it is generally agreed upon that EH is a consistent histological hallmark of the disease, a phenomenon seen in numerous temporal bone studies[4-7]. EH can be described as a pathologic finding in which the structures bounding the endolymphatic space are distended by an enlargement of endolymphatic volume[8]. The consequent hydropic state leads to various mechanical and chemical perturbations that ultimately give rise to the classic symptoms of MD.

In the cochlea, distension of the scala media causes the endolymphatic space to impinge on the bordering perilymphatic compartments. According to Wit *et al*[9] the degree of distension is related to the mechanical compliance of the membrane involved. This explains why EH is more prevalent in the cochlea and saccule, which are relatively more compliant than other structures such as the utricle or semicircular canals. Long-term distension may eventually lead to rupture of inner ear membranes. For example, rupture of Reissner’s membrane has been reported in patients with MD, although Paparella and Djalilian (2002) note the absence of rupture in two thirds of patients. Nonetheless, it has been theorized that membrane rupture leads to an electrolyte imbalance, causing acute vertigo and hearing loss[4,5,8,10,11].Chemically, the hydropic state also creates a neurotoxic environment that leads to apoptosis of spiral ganglion cells[5].Excitotoxicity may therefore contribute to the auditory symptoms of MD.

Previous research has shown that almost all patients diagnosed with MD present with EH in the affected ear. However, this consistent finding does not imply that EH is the direct underlying cause of MD. Several studies involving histopathological examinations of human temporal bones have revealed that not every patient with EH presents with symptoms of MD[4,12,13]. This makes it difficult to infer a simple cause-and-effect relationship. Instead, EH may represent result of various etiologies that disrupt normal endolymphatic fluid homeostasis. Semaan and Megerian (2010) separate these etiopathogenic factors into intrinsic or extrinsic. Intrinsic factors may include hypoplasia of labyrinthine structures, anteriorly and medially displaced sigmoid sinus, genetic factors, and other causes attributable to the inner ear itself. Extrinsic factors include autoimmune disease, allergy, otosclerosis, viral infection and trauma[5].

***Genetics***

Genetically, MD follows an autosomal dominant pattern with 60% penetrance[14]. Koyama *et al*[15] (1993) found relatively higher levels of histocompatibility antigens in affected patients, with HLA-DR, DQ, DP, A2 and B44 being particularly noteworthy[16]. Furthermore, a missense mutation of the COCH gene in the DFNA9 locus has been shown to produce MD-like symptoms such as progressive sensorineural hearing loss and vestibular dysfunction[17]. However, Morrison and Johnson propose that the COCH gene is an unlikely candidate for MD[18]. Lastly, an animal model of postnatal EH in mice suggests that genetics may play a role in posttranscriptional modification of the gene product, which also explains phenotypic differences between patients[5]. Overall, investigations into the genetic basis of MD suggest that multiple genes may be involved, and in combination they render certain individuals more susceptible to developing the disease.

***Autoimmunity***

 It is believed that the immunological basis of the pathogenesis of MD may involve reactions between antibodies and tissue antigens, or IgG- and IgM-mediated circulating immune complexes (CICs)[19].While larger CICs are cleared from circulation, smaller complexes can continue to circulate and accumulate in inner ear tissues, causing a local inflammatory response[19]. Deposition within the stria vascularis and endolymphatic sac may even lead to increased vascular permeability, and the sudden efflux of fluid induces EH and even rupture of Reissner’s membrane[20]. Success with steroid-based treatments, which act as an anti-inflammatory agent, also bolsters the argument for an immunologic mechanism in the development of MD[5]. Furthermore, other studies note the presence of intraluminal eosinophilic material within the endolymphatic duct, and conclude that it is evidence of an immunodefensive system in the inner ear as this material contains the macrophages that trap antigen[21,22].

***Endolymphatic duct and sac***

 The longitudinal flow theory states that the unidirectional flow of endolymph begins in the stria vascularis where it is produced, travels through the endolymphatic duct, and is eventually absorbed by the endolymphatic sac[5]. Thus, it follows that narrowing of the endolymphatic duct could impair endolymph absorption at the sac, and consequently result in a hydropic state. In fact, numerous guinea pig models show the development of hydrops following surgical obstruction of the endolymphatic duct[4]. However, Salt and colleagues found that the hydropic state could not be a result of the blockage of longitudinal flow because the rate of endolymph flow was too small. Instead, they believe that endolymphatic homeostasis is not volume-dependent; rather, it is dominated by ion transport and water equilibration *via* osmotic gradients[23,24]. Shinomori *et al*[25] (2001) further this idea by proposing a cytochemical mechanism for the development of hydrops. After blocking the endolymphatic duct in 22 guinea pigs, changes were noted in the cytochemistry of type I and II fibrocytes as well as nonsensory epithelial cells before the development of hydrops. Blocking the endolymphatic duct changed the composition of perilymph, thus placing osmotic stress on fibrocytes, which are important in maintaining fluid homeostasis. Merchant *et al*[4] hypothesizes that the dysfunction of fibrocytes interferes with K+ recycling, leading to osmotic imbalance and expansion of the endolymphatic compartment.

**CLASSIFICATION**

The criteria for diagnosis of MD have undergone various changes within the past few decades. In 1974, the Japanese Society for Equilibrium Research proposed a set of conditions that classified the disorder into either *definite*or *suspicious/uncertain*MD. Lopez-Escamez *et al*[26] briefly outlined those conditions as the following: (1) repeated attack of whirling vertigo; (2) fluctuating cochlear symptoms; and (3) exclusion of central nervous system involvement, VIII nerve tumor and other cochleovestibular diseases. A diagnosis of definite MD required fulfillment of all three conditions while suspicious/uncertain MD involved two of the conditions with the third being necessarily included[26].

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also developed a set of guidelines in 1972, which were revised in 1985 and again in 1995. Nearly all studies since then have been based on the 1995 criteria, which classified MD into possible, probable, definite and certain[27] (Table 1). A recent collaboration among the Equilibrium Committee of the AAO-HNS, the Japan Society for Equilibrium Research, the European Academy of Otology and Neuro-Otology (EAONO), the Korean Balance Society and the Bárány Society gave rise to a new set of guidelines for the diagnosis and classification of MD (Table 2). The aim was to develop international consensus criteria for MD to improve the quality of data collected from patients. Furthermore, clarification was needed with regards to the nature of auditory symptoms[26].

**DIAGNOSIS**

***Audiogram***

Traditionally, the most common audiometric configuration for patients with MD involved a “rising” pattern during the early stages, indicating low frequency hearing loss, followed by a flat audiogram in later stages of the disease[28-30].However, Opheim and Flottorp began to notice a pattern involving a “peak” audiogram in many of their patients with MD[31]. Further investigations have been conducted in order to assess the usefulness of the peak audiogram as a diagnostic tool. In one study, 363 hearing impaired ears with MD were assessed for evidence of a peak audiogram. Paparella *et al*[28] (1982) noted the presence of a peak audiogram “if the air conduction threshold for one test frequency was at least 10 dB better than both hearing thresholds for the two adjacent octave frequencies”. The reported sensitivity of the peak audiogram in detecting MD was 41.7%, while the specificity was 93.4%[28]. Therefore, the audiogram appears to be useful in ruling out the possibility of MD in patients without a peak configuration. However, its low sensitivity makes it a poor diagnostic tool on its own. Perhaps the peak audiogram may best be used as an adjunctive test to more advanced imaging techniques.

In a separate study by Lee *et al*[29], other audiometric patterns were considered in addition to the peak configuration. These included flat, rising, falling and dip configurations. The results once again supported a relatively higher proportion of the peak audiogram (50.65%), followed by the falling audiogram (26.26%), the dip audiogram (9.24%), and other types accounting for the remaining portion[29]. Again, the low sensitivity of the peak audiogram makes it an unreliable diagnostic test for MD, and this study along with others show the involvement of a wider variety of configurations.

Paparella *et al*[28] also found that those with severe or profound hearing loss were just as likely to have a 2000 Hz peak audiogram as those with mild or moderate hearing loss. This implies that the prevalence of the peak audiogram is unrelated to the degree of hearing loss. Instead, prevalence of the peak audiogram appears to be affected by bilaterality and duration: bilateral peak configurations are more likely to result in patients with bilateral diseased ears of longer duration[28].

***Magnetic resonance imaging***

The use of magnetic resonance imaging (MRI) as a diagnostic tool for identifying EH gained popularity in 2007. Nakashima *et al*[32] (2007) used 3-T MRI following transtympanic (TT) gadolinium injection to visualize the endolymphatic space of patients diagnosed with MD, and since then it has been regarded as a possible gold standard test. It is also worth noting that a modified method involves intravenous (*iv*) administration of gadolinium.

The main outcome measure in using MRI as a diagnostic tool is perilymphatic enhancement in various portions of the labyrinth. Perilymphatic enhancement is an indirect measure of EH with progressively lower enhancement representing growing occupation of the perilymphatic space by the hydrops[33]. For example, in the cochlea, decreased visualization of the scala vestibuli indirectly infers increased displacement of Reissner’s membrane brought about by EH[34]. Though perilymphatic enhancement is a reliable tool for inferring the presence of hydrops, the possibility of false positive findings cannot be ruled out. This could be due to impaired filtration of gadolinium into the perilymphatic compartment as a result of degenerative changes in the inner ear[33].

Gadolinium injection followed by MRI appears to be a well-tolerated test with good image quality, and relatively few, if any, complications have been reported[35,36]. Furthermore, numerous studies support a high sensitivity of the test for identifying EH in symptomatic ears, whether the contrast is administered intravenously or using the TT method. Recent studies investigating the use of MRI as a diagnostic test report a relatively consistent sensitivity as high as 90%-100%[33,36,37]. These results are comparable with previous investigations and bolster the usefulness of MRI as a diagnostic tool for the presence of EH in symptomatic ears. It is worth noting a recent study that compared MRI with tone burst electrocochleography (ECoG) in the diagnosis of MD. The sensitivity results with MRI differed significantly from previous studies, reporting 47%, 29%, and 8% for definite, probable and possible MD respectively[35].

While gadolinium-enhanced MRI shows promise as a reliable tool for positively identifying hydrops in patients with MD, its specificity requires further investigation. Few studies have been conducted on this measure and the results are variable. For example, Pyykkő *et al*[37] found that MRI visualized EH in 65% of asymptomatic ears (35% specificity). In contrast, other studies yield better results in terms of correctly not identifying hydrops on MRI in asymptomatic ears. Baráth *et al*[34] used IV Gadolinium injection followed by MRI to look for hydrops in 53 patients with MD, reporting a specificity of 78%. Fiorino *et al*[33] had even better results with TTGad injection, noting no perilymphatic enhancement defects in all unaffected contralateral ears of patients with MD (100% specificity).

Generally, TTGad injection is preferred over the IV route because it provides a higher perilymphatic signal and thus a better visualization of the compartment[38]. However, the advantages of IV injection should not be ignored and perhaps could be used in special cases. Of particular importance is its less invasive nature, the ability to simultaneously examine both ears for comparison and the fact that perilymphatic enhancement is independent of the status of the round window membrane[34,39].

***ECoG***

ECoG is a technique that measures the electric potentials generated in the cochlea in response to an auditory signal. The usual ECoG response consists of a cochlear microphonic (CM), the summating potential (SP) and the cochlear nerve compound action potential (AP). The CM is mainly generated by the outer hair cells closest to the recording electrode. Due to its proximity, the CM closely resembles the waveform of the stimuli and vibrations of the basilar membrane. If the polarity of the stimulus is reversed, the polarity of the CM will also reverse. The alternate polarity stimuli are used to cancel the amplitude of the CM so that SP and AP can be measured. The SP consists of a shift in the baseline of a CM in response to click stimuli and a deflection before the AP in response to tone-burst stimuli. Finally, the AP is the sum of the individual APs from the auditory nerve fibers[40].Two methods of obtaining ECoG differ by where the electrode is placed: TT has an electrode on the promontory wall of the middle ear and Extratympanic (ET) has one outside of the tympanic membrane. The ET method has a slightly lower sensitivity and specificity because of low signal amplitude, but is still the preferred method due to it being non-invasive and easy to implement. Using tone burst auditory stimuli is more reliable than the commonly used auditory clicks stimuli[41].

The SP/AP ratio is commonly used to identify EH. The thresholds for the ratio vary with some authors saying 0.5 for ET with clicks and alternating polarity while others saying 0.33 for TT. There is no universally agreed SP/AP ratio that we could find[41]. It is thought that altered SP and AP is the result of mechanical asymmetry in the basilar membrane[42].

Electrovestibulography (EVestG) is similar to ECoG except that it measures saccule function instead of cochlear function. Instead of acoustic stimuli, the patient experiences passive whole body tilts in a hydraulically controlled chair located in an electrically and acoustically shielded chamber. The test has shown encouraging results in other neurological diagnostic applications such as Parkinson’s disease, depression, and schizophrenia disorder by other studies. It is possible that with more research, EVestG could be used to identify neural firing patterns that are diagnostic in patients with MD[43].

Sensitivity of ECoG ranges from 57% to 71% and specificity ranges from 94% to 96%[41]. A study found 1 kHz tone-burst stimuli to be the most reliable stimuli with a sensitivity of 86% and specificity of 80.5%[44]. ECoG interpretation is complicated by the fluctuating behavior of MD. Sensitivity can go from 60% to 92% when ECOG is used during a symptomatic period[41].Additionally, sensitivity is found to increase with duration and severity of the disease. A study found 71% sensitivity in stage 1 MD compared to 90% in stage 4, and 43% in MD for less than 1 year duration compared to 100% in 30 years duration[45]. However, ECoG is not a useful tool in differentiating between definite and probable MD[41] .

***Vestibular evoked myogenic potentials***

Vestibular evoked myogenic potentials (VEMPs) are becoming a popular tool to assess inner ear function. Cervical VEMPs (cVEMPs) utilize the vestibulocolic reflex by measuring the inhibitory potentials of the ipsilateral sternocleidomastoid muscle in response to loud auditory signals. Signals from the acoustically responsive sensory cells and neurons of the saccule are conducted centrally *via* the inferior vestibular nerve[46]. Studies have shown that altered motion mechanics of the distended saccule can lead to an altered VEMP response in MD patients[46]. A cVEMP curve is made by plotting the dB SPL as a function of frequency for tone bursts at 250, 500, 750 and 1000 Hz. Healthy patients are most sensitive at 500 Hz and patients with MD showed a sensitivity shift to 1000 Hz[47].30% of unaffected ears in patients with unilateral MD also show a sensitivity shift, but to a lesser degree. This could be because the unaffected ear has a minor form of MD. It was found that normal adults above the age of 60 show a sensitivity shift. In some cases they showed flattening of the threshold response curve. A high proportion of patients with caloric asymmetry ≥ 25% did not show any VEMP response[47].

Another version of VEMP called ocular VEMP (oVEMP) records excitatory potentials from the superior vestibular nerve going to the inferior oblique and inferior rectus muscles of the opposite side[48,49].It is thought that utricular afferents and some saccular afferents travel through the superior nerve division and most saccular afferents travel through the inferior division. With more research, VEMPs could be used to differentiate dysfunction in the otolith and saccule[50].VEMP measurement has been found to be a more reliable test for saccule function compared to a calorics[51]. It has been suggested that a negative VEMP test does not rule out MD, however a positive test result suggests that MD is probable[47].

**MIGRAINE AND MÉNIÈRE’S**

 Since the term MD was first coined, the prevalence of migraine among MD patients and MD among migraine patients has suggested a possible link between these two diseases[52]. What was once called Vestibular Ménière’s is no longer recognized by the current guidelines for MD[53]. Others suggest that most likely this variant of MD was actually undiagnosed vestibular migraine (VM)[54,55].

Recently, the Migraine Classification Subcommittee of the International Headache Society has proposed diagnostic criteria for VM which have been included in the International Classification of Headache Disorders (ICHD) 3rd beta edition. It should be noted that the term VM could be used interchangeably in other papers with migraine-associated dizziness/vertigo and migrainous vertigo. According to the ICHD, VM is characterized by vestibular symptoms such as vertigo and head motioned-induced dizziness lasting between 5 minand 72 h. Common symptoms in MD such as tinnitus, aural pressure and fluctuating hearing loss other than profound can occur in VM. Likewise, migraine headaches, photophobia and even migraine auras are common in MD[56]. A pathophysiological relationship between MD and VM remains uncertain however some theories have been proposed. The prevalence of allergy among MD and migraine patients compared to the general population may suggest an immunological link[57].There is some evidence of increased IgE levels in MD patients that could lead to EH in MD and meningeal vasculature changes in migraines[57,58]. However, more work needs to be done in this area to support this claim.

Early MD can present with early episodic vertigo only and can be difficult to separate from VM. Differentiating MD from VM can be done through the patient’s history or by means of vestibular function tests[56]. In VM the spells of vertigo can be anywhere from few minutes to over 24 h. Migraine is more likely the source of vertigo if there are associated features like photophobia, paresthesia, visual disturbances (scintillating lights, visual hallucinations). Meanwhile, patients with MD will eventually develop a progressive hearing loss. In VM while audiometric and  vestibular test findings can be found, they are typically mild and do not fluctuate over time[52].A recent study using VEMP separated MD from VM with a sensitivity of 90% and specificity of 70%[59]. Shepard suggests that if VM is likely, even though MD has not been ruled out, it is better to treat for migraine. Even in cases where both migraine and MD coexist, it is better to treat migraine first[52].

**TREATMENTS**

***Dietary/salt restrictions***

The typical first treatment option for an MD patient is a low salt diet consisting of sodium in the range of 1000 mg to 2000 mg per day[60,61]. Some patients with MD report that a salt binge seems to precede an acute episode of MD[61]. The purpose of the diet is to reduce endolymphatic pressure, due to the idea that a high-salt diet can influence the osmotic gradients in the inner ear to develop hydrops[61]. Some however have challenged the idea that a salt diet could affect the plasma sodium level or fluid dynamics in the inner ear. Sodium levels in endolymph have been found to be normal in animals with induced EH and patients from which endolymph were sampled. Thai-Van *et al*[62] suggests the alternative theory that a low sodium intake influences aldosterone secretion that may affect endolymph regulation.

There have been some reports that a low sodium diet associated with diuretics brings positive result[63,64]. However, the evidence in the literature to support low sodium diet as an effective treatment for MD has been lacking. A low salt diet can limit the patient’s lifestyle and quality of life. This can often make it difficult to remain on the diet in the long-term[61].

***Diuretics***

Diuretics are relatively inexpensive and commonly used to treat MD[60].The purposes of diuretics are to alter ion concentrations in order to reduce endolymphatic volume and pressure. Some have argued against the use of diuretics saying that there are too many active mechanisms and buffer systems in the inner ear for diuretics to be useful[65]. As previously noted, smaller studies have found that the use of diuretics with a low salt diet can be beneficial[63,64].A recent Cochrane review found no evidence in support for or against the use of diuretics because of the lack of articles that meet accepted review standards[66]. Common side effects are weakness, dizziness and headache. Serious side effects are cardiac arrhythmias, hyperkalemia, renal failure and hypersensitivity[67]. Side effects are much more prevalent in the elderly population[68]. It is important to avoid drugs that increase serum potassium concentration and antiarrhythmic drugs because Dyazide can potentiate toxicity. In addition, Dyazide interacts with methotrexate, lithium, cyclophosphamide, pixantrone, and others[67]. Pirodda *et al*[65] suggests diuretics lower blood pressure, which can exaggerate a vasomotor response inducing local ischemia, which can lead to damage.

***Betahistine***

Betahistine is one of the most widely used drugs to treat MD, with 94% of surgeons prescribing it in the Europe and United Kingdom[60]. In addition to being an H1 agonist and an H3 antagonist, it is thought to promote blood flow into the cochlea through the stria vascularis by its suspected vasodilatory effects[69]. Several clinical trials have shown that Betahistine may in some way improve vertigo, nausea and vomiting[70-74]. However, long term, longitudinal, uncontrolled trials have failed to show a benefit on hearing loss[75,76]. A Cochrane review looking at 243 patients concluded that there is insufficient evidence for the effectiveness of betahistine[77]. Some suggest that it should not be considered the gold standard therapy for MD[78]. However, others say that Betahistine is a cheap drug with limited side effects and that if there is no improvement it should be withdrawn[68].Bronchospasms, asthma, drowsiness, lethargy, nausea, headache, eye and skin irritation, peptic ulcers due to its histamine-like activity, mild stomach discomfort[79-81].However, systematic reviews still tend to underreport the side effects[82].

***TT steroid***

 Steroids have been used to treat an autoimmune response, ischemia and sudden sensorineural hearing loss, all of which have made it a likely candidate for the treatment of MD[61,67,83].Studies show that steroids can also have mineralocorticoid effects. Dexamethasone increases the principal epithelial sodium transporter of semicircular canals by threefold, possibly influencing the sodium and fluid dynamics in the inner ear[84].

An older study showed promising results, with 82% of patients having improved vertigo when treated with steroids compared to 57% treated with saline injections[85].One trial showed that 91% of MD patients had adequate control with intratympanic dexamethasone injections and did not require more ablative treatments[86]. A recent review looking at 5 RCT’s found that there is enough evidence to support the effectiveness of intratympanic steroid for treating vertigo[87]. There is a small risk of tympanic membrane perforation and middle ear inflammation[67].

***TT gentamicin***

Gentamicin is an aminoglycoside antibiotic that is used as an ablative treatment for MD. Although both vestibulotoxic and cochleotoxic, the drug has a high affinity for type 1 vestibular hair cells and therefore results in more vestibular damage than hearing loss[88]. Gentamicin is thought to operate by accumulating in hair cells and also interfering with calcium dependent receptors in the plasma membrane by competitive inhibition[89,90]. Aminoglycosides can also interfere with hair cell secondary cell messengers and the integrity of the cell membrane[91]. The drug is titrated to control vertigo symptoms, although some argue to titrate until there are signs of unilateral vestibular weakness. The main goal is to titrate just enough to get the most reduction of vertigo with the smallest reduction of hearing and balance. Titration of gentamicin until there is complete unilateral vestibular ablation is usually unnecessary and can result in worse hearing and balance outcomes[67].

Gentamicin has been shown to be an effective treatment for vertigo with minimal vestibular loss compared to ablative surgeries[87,92]. One RCT comparing intratympanic gentamicin to saline found a reduction of vertigo with an average reduction in hearing thresholds of only 8 dB[93]. Another RCT comparing intratympanic gentamicin to dexamethasone found greater control of vertigo with gentamicin, with minimal hearing damage[94]. Typically 54% of patients only require one injection and 96% do not need further ablative surgeries[95]. Clinical evidence shows that anatomic factors such as adhesions or bone dust can prevent drug uptake by blocking the round window. Middle ear exploration with exposure of the round window membrane and direct application of gentamicin is effective at controlling vertigo in 75% of gentamicin non-responders[96].

Resultant unilateral vestibular hypofunction can cause symptoms of imbalance with rapid ipsilateral head turns[97]. Hearing loss can occur in 17% to 25% of patients[98,99].

***Meniett therapy***

The Meniett device operates by adding positive pressure to the middle ear, which has shown to influence pressure in the inner ear[100]. This is a noninvasive procedure that involves a short-term ventilation tube and consists of a repeated 0.6-se pulse at a range of 0 to 20 cm H20 at 6 Hz applied to the middle ear. The treatment consists of three to four cycles per day with each cycle lasting for 5 min[101].It is thought that the pulses vibrate the round window aiding in endolymphatic turnover[67].

A 2014 meta-analysis looking at 12 studies including 2 RCTs found that the device improved short-term vertigo and some hearing[101]. A recent Cochrane review from 2015 looked at 5 RCTs and found that only one showed an improvement in vertigo with positive pressure therapy[102].

The Cochrane review found moderate quality evidence in two studies that hearing is worsened after use of the device[102].The Meniett device is minimally invasive other than the associated risks of inserting a ventilation tube.

***Endolymphatic sac surgery***

The endolymphatic sac is an outpouching of the endolymphatic membrane in contact with the dura of the temporal bone[67]. It was originally thought to be involved in the resorption of endolymph but more recently was found to also have an immune function[103]. Endolymphatic sac surgery is aimed at shunting, draining or decompressing the sac, which is thought to prevent hydrops by facilitating outflow of endolymph[67]. Similar results have been noted in decompressing the sac versus shunting[104]. The most common shunting technique is the endolymphatic mastoid shunt which involves draining endolymph from the sac into the mastoid cavity[105]. A histological study looked at temporal bones after sac surgery and found that correct placement of the shunt had no relation to vertigo improvement[106]. Ghossaini *et al*[107] noted that in situations when the endolymphatic sac cannot be found, decompressing the surrounding dura gives positive results. Additionally, it is possible that removing the bone surrounding the endolymphatic sac could also lead to decompression[107].

Endolymphatic sac surgery, although invasive, is considered a conservative approach because it leaves the vestibular neuroepithelium and innervation intact. Unilateral MD patients with intractable vertigo and especially bilateral MD patients that do not respond to medical treatments are considered for endolymphatic surgery in order to avoid possible hearing loss with ablative treatments[107]. Some trials have found high rates of long-term improvement in vertigo with low risk of hearing loss[108,109]. Some studies report 55% to 85% hearing stabilization or improvement[110-112].However, a Cochrane review in 2013 noted that 2 RCTs found no difference between treatment and placebo groups[113]. It should be noted that the low number of patients considered for surgery out of the already low number of patients unresponsive to medical treatment makes it difficult to obtain high-level evidence. Patients who had good primary results from endolymphatic surgery but experience recurrence of symptoms after a period of time can be considered for revision sac surgery. The idea is that iatrogenic osteogenesis and perisaccular fibrosis reestablishes the pathogenic state by compromising endolymphatic drainage[114-116].Huang[117] found that perisaccular fibrosis is linked with recurrence of symptoms after surgery.It has been shown that correctional surgery will provide symptom relief[114]. Some reports show that use of intraoperative mitomycin C to the endolymphatic sac area may prevent perisaccular fibrosis[117].Endolymphatic sac surgery has a small risk to residual hearing, up to 2%[118]. Bleeding from the lateral sigmoid sinus and cerebrospinal fluid leak are other potential complications in endolymphatic sac surgery. Conductive hearing loss after endolymphatic sac surgery has been reported and is thought to be secondary to bone dust making its way to the middle ear[118].

***Vestibular nerve section***

The purpose of vestibular nerve section (VNS) is to treat vertigo by selectively cutting the vestibular portion of CN VIII while preserving the cochlear portion. This surgery is usually the last option for clinicians when dealing with unilateral MD patients with hearing function that have exhausted all other medical and surgical treatments. Patients without hearing function would be considered for a labyrinthectomy. Patients with bilateral vestibular disease are not considered for a vestibular nerve section because of the oscillopsia and permanent imbalance that can result from bilateral vestibular loss[107].VNS can be accomplished through either retrosigmoid or retrolabyrinthine approach. The retrosigmoid approach requires a suboccipital craniotomy and the retrolabryinthine approach requires mastoidectomy. Both usually involve decompression of the internal auditory canal in order to identify and section the vestibular nerve. Care must be taken in order to avoid injuring the facial and cochlear nerve[67]. VNS is the most effective treatment for vertigo in MD[107].Vertigo control rates between 78% and over 90% have been reported in the literature[119-124].Possible reasons for failure are incomplete sectioning of the vestibular nerve in order to avoid injury to the cochlear nerve and inability to identify the vestibulocochlear cleavage plane[125]. Remaining or recurrent vertigo after surgery can be further treated by intratympanic gentamicin[107].About 4% of patients experience significant hearing loss[124].Other complications are facial nerve paralysis, cerebrospinal fluid leak, and headache[107].

***Labyrinthectomy***

Labyrinthectomy is a destructive treatment involving the removal of the neuroepithelium from the five vestibular organs. The treatment is typically the last resort for unilateral MD patients with severe hearing loss that do not respond to medical and surgical treatments. As was the case for vestibular nerve section, bilateral MD is a contraindication because of the oscillopsia and permanent imbalance that can result from bilateral vestibular loss[107].Several studies have shown excellent control of vertigo in up to 97% of patients[16,126,127]. There is a 2% risk of facial nerve injury and a 3% risk of CSF leak[128].

**CONCLUSION**

The pathophysiology of MD is still unclear and controversial, however EH represents the hallmark histological finding in postmortem temporal bone studies of patients. More than likely, it represents the end point of various causes. As we become more experienced with evaluating these patients it is necessary to fine tune the diagnostic criteria for improved communication and improve the reporting of research data across specialties. The new international consensus on diagnostic criteria is an important step towards this.

The diagnosis of MD can be difficult and many commonly used tests are poor screening tools. More specific diagnostic methods are needed to fine-tune the diagnosis and to help differentiate MD from Migraine associated vertigo. Recently MRI for identifying EH has gained popularity.

Finally, new and less invasive and destructive treatments of MD are available with the introduction of intratympanic treatments with steroids and gentamicin as well as the Meniett device.

**REFERENCES**

1 **Alexander TH**, Harris JP. Current epidemiology of Meniere's syndrome. *Otolaryngol Clin North Am* 2010; **43**: 965-970 [PMID: 20713236 DOI: 10.1016/j.otc.2010.05.001]

2 **Baloh RW**. Prosper Ménière and his disease. *Arch Neurol* 2001; **58**: 1151-1156 [PMID: 11448308 DOI: 10.1001/archneur.58.7.1151]

3 **Yamakawa K**. Über die pathologische Veränderung beieinem Meniere-Kranken. *J Otorhinolaryngol Soc Jpn* 1938; **44**: 2310–2312

4 **Merchant SN**, Adams JC, Nadol JB. Pathophysiology of Meniere's syndrome: are symptoms caused by endolymphatic hydrops? *Otol Neurotol* 2005; **26**: 74-81 [PMID: 15699723]

5 **Semaan MT**, Megerian CA. Contemporary perspectives on the pathophysiology of Meniere's disease: implications for treatment. *Curr Opin Otolaryngol Head Neck Surg* 2010; **18**: 392-398 [PMID: 20639763 DOI: 10.1097/MOO.0b013e32833d3164]

6 **Paparella MM**, Morizono T, Matsunaga T. Kyoshiro Yamakawa, MD, and temporal bone histopathology of Meniere's patient reported in 1938. Commemoration of the centennial of his birth. *Arch Otolaryngol Head Neck Surg* 1992; **118**: 660-662 [PMID: 1637546 DOI: 10.1001.archotol.1992.01880060110023]

7 **Hallpike CS**, Cairns H. Observations on the Pathology of Ménière's Syndrome: (Section of Otology). *Proc R Soc Med* 1938; **31**: 1317-1336 [PMID: 19991672 DOI: 10.1017/S0022215100003947]

8 **Salt AN**, Plontke SK. Endolymphatic hydrops: pathophysiology and experimental models. *Otolaryngol Clin North Am* 2010; **43**: 971-983 [PMID: 20713237 DOI: 10.1016/j.otc.2010.05.007]

9 **Wit HP**, Warmerdam TJ, Albers FW. Measurement of the mechanical compliance of the endolymphatic compartments in the guinea pig. *Hear Res* 2000; **145**: 82-90 [PMID: 10867280 DOI: 10.1016/S0378-5955(00)00078-2]

10 **Paparella MM**, Djalilian HR. Etiology, pathophysiology of symptoms, and pathogenesis of Meniere's disease. *Otolaryngol Clin North Am* 2002; **35**: 529-545, vi [PMID: 12486838 DOI: 10.1016/S0030-6665(02)00019-1]

11 **Sando I**, Orita Y, Hirsch BE. Pathology and pathophysiology of Meniere's disease. *Otolaryngol Clin North Am* 2002; **35**: 517-528 [PMID: 12486837 DOI: 10.1016/S0030-6665(02)00020-8]

12 **Belal A**, Antunez JC. Pathology of endolymphatic hydrops. *J Laryngol Otol* 1980; **94**: 1231-1240 [PMID: 7441041 DOI: 10.1017/S0022215100090058]

13 **Rauch SD**, Merchant SN, Thedinger BA. Meniere's syndrome and endolymphatic hydrops. Double-blind temporal bone study. *Ann Otol Rhinol Laryngol* 1989; **98**: 873-883 [PMID: 2817679 DOI: 10.1177/000348948909801108]

14 **Morrison AW**. Anticipation in Menière's disease. *J Laryngol Otol* 1995; **109**: 499-502 [PMID: 7642988 DOI: 10.1017/S0022215100130567]

15 **Koyama S**, Mitsuishi Y, Bibee K, Watanabe I, Terasaki PI. HLA associations with Menière's disease. *Acta Otolaryngol* 1993; **113**: 575-578 [PMID: 8266781 DOI: 10.3109/00016489309135866]

16 **Hammerschlag PE**, Schuknecht HF. Transcanal labyrinthectomy for intractable vertigo. *Arch Otolaryngol* 1981; **107**: 152-156 [PMID: 7469903 DOI: 10.1001/archotol.1981.00790390018006]

17 **de Kok YJ**, Bom SJ, Brunt TM, Kemperman MH, van Beusekom E, van der Velde-Visser SD, Robertson NG, Morton CC, Huygen PL, Verhagen WI, Brunner HG, Cremers CW, Cremers FP. A Pro51Ser mutation in the COCH gene is associated with late onset autosomal dominant progressive sensorineural hearing loss with vestibular defects. *Hum Mol Genet* 1999; **8**: 361-366 [PMID: 9931344 DOI: 10.1093/hmg/8.2.361]

18 **Morrison AW**, Johnson KJ. Genetics (molecular biology) and Meniere's disease. *Otolaryngol Clin North Am* 2002; **35**: 497-516 [PMID: 12486836 DOI: 10.1016/S0030-6665(02)00018-X]

19 **Filipo R**, Mancini P, Nostro G. Ménière's disease and autoimmunity. *Ann N Y Acad Sci* 1997; **830**: 299-305 [PMID: 9616688]

20 **Derebery MJ**, Rao VS, Siglock TJ, Linthicum FH, Nelson RA. Menière's disease: an immune complex-mediated illness? *Laryngoscope* 1991; **101**: 225-229 [PMID: 1825685]

21 **Lundquist PG**. Aspects on endolymphatic sac morphology and function. *Arch Otorhinolaryngol* 1976; **212**: 231-240 [PMID: 990076 DOI: 10.1007/BF00453671]

22 **Rask-Andersen H**, Stahle J. Immunodefence of the inner ear? Lymphocyte-macrophage interaction in the endolymphatic sac. *Acta Otolaryngol* 1980; **89**: 283-294 [PMID: 7395499 DOI: 10.3109/00016488009127140]

23 **Salt AN**, Thalmann R, Marcus DC, Bohne BA. Direct measurement of longitudinal endolymph flow rate in the guinea pig cochlea. *Hear Res* 1986; **23**: 141-151 [PMID: 3745017 DOI: 10.1016/0378-5955(86)90011-0]

24 **Salt AN**. Regulation of endolymphatic fluid volume. *Ann N Y Acad Sci* 2001; **942**: 306-312 [PMID: 11710472 DOI: 10.1111/j.1749-6632.2001.tb03755.x]

25 **Shinomori Y**, and Adams JC. Changes in immunostaining for Na, K, 2Cl-cotransporter 1, taurine and c-Jun N-terminal kinase in experimentally induced endolymphatic hydrops. *ARO Abstr* 2001; **24**: 134

26 **Lopez-Escamez JA**, Carey J, Chung WH, Goebel JA, Magnusson M, Mandalà M, Newman-Toker DE, Strupp M, Suzuki M, Trabalzini F, Bisdorff A. Diagnostic criteria for Menière's disease. *J Vestib Res* 2015; **25**: 1-7 [PMID: 25882471 DOI: 10.3233/VES-150549]

27 Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. *Otolaryngol Head Neck Surg* 1995; **113**: 181-185 [PMID: 7675476]

28 **Paparella MM**, McDermott JC, de Sousa LC. Meniere's disease and the peak audiogram. *Arch Otolaryngol* 1982; **108**: 555-559 [PMID: 7115184 DOI: 10.1001/archotol.1982.00790570021005]

29 **Lee CS**, Paparella MM, Margolis RH, Le C. Audiological profiles and Menière's disease. *Ear Nose Throat J* 1995; **74**: 527-532 [PMID: 7555870]

30 **Thomas K**, Harrison MS. Long-term follow up of 610 cases of Ménière's disease. *Proc R Soc Med* 1971; **64**: 853-857 [PMID: 5569327]

31 **Opheim O**, Flottorp G. Menière's disease; some audiological and clinical observations. *Acta Otolaryngol* 1957; **47**: 202-218 [PMID: 13410572]

32 **Nakashima T**, Naganawa S, Sugiura M, Teranishi M, Sone M, Hayashi H, Nakata S, Katayama N, Ishida IM. Visualization of endolymphatic hydrops in patients with Meniere's disease. *Laryngoscope* 2007; **117**: 415-420 [PMID: 17279053]

33 **Fiorino F**, Pizzini FB, Beltramello A, Mattellini B, Barbieri F. Reliability of magnetic resonance imaging performed after intratympanic administration of gadolinium in the identification of endolymphatic hydrops in patients with Ménière's disease. *Otol Neurotol* 2011; **32**: 472-477 [PMID: 21307806 DOI: 10.1097/MAO.0b013e31820e7614]

34 **Baráth K**, Schuknecht B, Naldi AM, Schrepfer T, Bockisch CJ, Hegemann SC. Detection and grading of endolymphatic hydrops in Menière disease using MR imaging. *AJNR Am J Neuroradiol* 2014; **35**: 1387-1392 [PMID: 24524921 DOI: 10.3174/ajnr.A3856]

35 **Hornibrook J**, Flook E, Greig S, Babbage M, Goh T, Coates M, Care R, Bird P. MRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of Ménière's Disease. *Otol Neurotol* 2015; **36**: 1109-1114 [PMID: 25985318 DOI: 10.1097/MAO.0000000000000782]

36 **Attyé A**, Dumas G, Troprès I, Roustit M, Karkas A, Banciu E, Pietras J, Lamalle L, Schmerber S, Krainik A. Recurrent peripheral vestibulopathy: Is MRI useful for the diagnosis of endolymphatic hydrops in clinical practice? *Eur Radiol* 2015; **25**: 3043-3049 [PMID: 25820480 DOI: 10.1007/s00330-015-3712-5]

37 **Pyykkö I**, Nakashima T, Yoshida T, Zou J, Naganawa S. Meniere's disease: a reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops. *BMJ Open* 2013; **3**: pii: e001555 [PMID: 23418296 DOI: 10.1136/bmjopen-2012-001555]

38 **Yamazaki M**, Naganawa S, Tagaya M, Kawai H, Ikeda M, Sone M, Teranishi M, Suzuki H, Nakashima T. Comparison of contrast effect on the cochlear perilymph after intratympanic and intravenous gadolinium injection. *AJNR Am J Neuroradiol* 2012; **33**: 773-778 [PMID: 22173762 DOI: 10.3174/ajnr.A2821]

39 **Silverstein H**, Rowan PT, Olds MJ, Rosenberg SI. Inner ear perfusion and the role of round window patency. *Am J Otol* 1997; **18**: 586-589 [PMID: 9303154]

40 **Adams ME**, Heidenreich KD, Kileny PR. Audiovestibular testing in patients with Meniere's disease. *Otolaryngol Clin North Am* 2010; **43**: 995-1009 [PMID: 20713239 DOI: 10.1016/j.otc.2010.05.008]

41 **Lamounier P**, Gobbo DA, Souza TS, Oliveira CA, Bahmad F. Electrocochleography for Ménière's disease: is it reliable? *Braz J Otorhinolaryngol* 2014; **80**: 527-532 [PMID: 25443316 DOI: 10.1016/j.bjorl.2014.08.010]

42 **Gatland DJ**, Billings RJ, Youngs RP, Johnson NP. Investigation of the physiological basis of summating potential changes in endolymphatic hydrops. *Acta Otolaryngol* 1988; **105**: 218-222 [PMID: 3389106 DOI: 10.3109/00016488809097001]

43 [**Dastgheib ZA**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dastgheib%20ZA%5BAuthor%5D&cauthor=true&cauthor_uid=25888785), [Lithgow B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Lithgow%20B%5BAuthor%5D&cauthor=true&cauthor_uid=25888785), [Blakley B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Blakley%20B%5BAuthor%5D&cauthor=true&cauthor_uid=25888785), [Moussavi Z](http://www.ncbi.nlm.nih.gov/pubmed/?term=Moussavi%20Z%5BAuthor%5D&cauthor=true&cauthor_uid=25888785). A new diagnostic vestibular evoked response. *J Otolaryngol Head Neck Surg* 2015; **44**: 14 [PMID: 25888785 DOI: 10.1186/s40463-015-0065-7]

44 **Iseli C**, Gibson W. A comparison of three methods of using transtympanic electrocochleography for the diagnosis of Meniere's disease: click summating potential measurements, tone burst summating potential amplitude measurements, and biasing of the summating potential using a low frequency tone. *Acta Otolaryngol* 2010; **130**: 95-101 [PMID: 19396716 DOI: 10.3109/00016480902858899]

45 **Ge X**, Shea JJ. Transtympanic electrocochleography: a 10-year experience. *Otol Neurotol* 2002; **23**: 799-805 [PMID: 12218638 DOI: 10.1097/00129492-200209000-00032]

46 **Rauch SD**, Zhou G, Kujawa SG, Guinan JJ, Herrmann BS. Vestibular evoked myogenic potentials show altered tuning in patients with Ménière's disease. *Otol Neurotol* 2004; **25**: 333-338 [PMID: 15129114]

47 **Zhu Y**, McPherson J, Beatty C, Driscoll C, Neff B, Eggers S, Shepard NT. Cervical VEMP threshold response curve in the identification of Ménière's disease. *J Am Acad Audiol* 2014; **25**: 278-288; quiz 302-303 [PMID: 25032972 DOI: 10.3766/jaaa.25.3.7]

48 **Weber KP**, Rosengren SM, Michels R, Sturm V, Straumann D, Landau K. Single motor unit activity in human extraocular muscles during the vestibulo-ocular reflex. *J Physiol* 2012; **590**: 3091-3101 [PMID: 22526888 DOI: 10.1113/jphysiol.2011.226225]

49 **Suzuki JI**, Tokumasu K, Goto K. Eye movements from single utricular nerve stimulation in the cat. *Acta Otolaryngol* 1969; **68**: 350-362 [PMID: 5309166 DOI: 10.3109/00016486909121573]

50 **Rosengren SM**, Kingma H. New perspectives on vestibular evoked myogenic potentials. *Curr Opin Neurol* 2013; **26**: 74-80 [PMID: 23254558 DOI: 10.1097/WCO.0b013e32835c5ef3]

51 **Egami N**, Ushio M, Yamasoba T, Yamaguchi T, Murofushi T, Iwasaki S. The diagnostic value of vestibular evoked myogenic potentials in patients with Meniere's disease. *J Vestib Res* 2013; **23**: 249-257 [PMID: 24284605 DOI: 10.3233/VES-130484]

52 **Shepard NT**. Differentiation of Ménière's disease and migraine-associated dizziness: a review. *J Am Acad Audiol* 2006; **17**: 69-80 [PMID: 16640061 DOI: 10.3766/jaaa.17.1.7]

53 **Paparella MM**, Mancini F. Vestibular Meniere's disease. *Otolaryngol Head Neck Surg* 1985; **93**: 148-151 [PMID: 3921902]

54 **Rassekh CH**, Harker LA. The prevalence of migraine in Menière's disease. *Laryngoscope* 1992; **102**: 135-138 [PMID: 1738284]

55 **Neuhauser H**, Leopold M, von Brevern M, Arnold G, Lempert T. The interrelations of migraine, vertigo, and migrainous vertigo. *Neurology* 2001; **56**: 436-441 [PMID: 11222783 DOI: 10.1212/WNL.56.4.436]

56 The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia* 2013; **33**: 629-808 [PMID: 23771276 DOI: 10.1177/0333102413485658]

57 **Sen P**, Georgalas C, Papesch M. Co-morbidity of migraine and Ménière's disease -- is allergy the link? *J Laryngol Otol* 2005; **119**: 455-460 [PMID: 15992471 DOI: 10.1258/0022215054273133]

58 **Hsu L**, Zhu XN, Zhao YS. Immunoglobulin E and circulating immune complexes in endolymphatic hydrops. *Ann Otol Rhinol Laryngol* 1990; **99**: 535-538 [PMID: 2195961 DOI: 10.1177/000348949009900707]

59 **Taylor RL**, Zagami AS, Gibson WP, Black DA, Watson SR, Halmagyi MG, Welgampola MS. Vestibular evoked myogenic potentials to sound and vibration: characteristics in vestibular migraine that enable separation from Meniere's disease. *Cephalalgia* 2012; **32**: 213-225 [PMID: 22259049 DOI: 10.1177/0333102411434166]

60 **Smith WK**, Sankar V, Pfleiderer AG. A national survey amongst UK otolaryngologists regarding the treatment of Ménière's disease. *J Laryngol Otol* 2005; **119**: 102-105 [PMID: 15829061 DOI: 10.1258/0022215053419871]

61 **Greenberg SL**, Nedzelski JM. Medical and noninvasive therapy for Meniere's disease. *Otolaryngol Clin North Am* 2010; **43**: 1081-1090 [PMID: 20713246 DOI: 10.1016/j.otc.2010.05.005]

62 **Thai-Van H**, Bounaix MJ, Fraysse B. Menière's disease: pathophysiology and treatment. *Drugs* 2001; **61**: 1089-1102 [PMID: 11465871]

63 **Boles R**, Rice DH, Hybels R, Work WP. Conservative management of Méniére's disease: Furstenberg regimen revisited. *Ann Otol Rhinol Laryngol* 1975; **84**: 513-517 [PMID: 1155886 DOI: 10.1177/000348947508400410]

64 **Santos PM**, Hall RA, Snyder JM, Hughes LF, Dobie RA. Diuretic and diet effect on Menière's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines. *Otolaryngol Head Neck Surg* 1993; **109**: 680-689 [PMID: 8233504]

65 **Pirodda A**, Ferri GG, Raimondi MC, Borghi C. Diuretics in Meniere disease: a therapy or a potential cause of harm? *Med Hypotheses* 2011; **77**: 869-871 [PMID: 21864986 DOI: 10.1016/j.mehy.2011.07.060]

66 **Thirlwall AS**, Kundu S. Diuretics for Ménière's disease or syndrome. *Cochrane Database Syst Rev* 2006; **(3)**: CD003599 [PMID: 16856015 DOI: 10.1002/14651858.CD003599]

67 **Sharon JD**, Trevino C, Schubert MC, Carey JP. Treatment of Menière's Disease. *Curr Treat Options Neurol* 2015; **17**: 341 [PMID: 25749846 DOI: 10.1007/s11940-015-0341-x]

68 **Syed I**, Aldren C. Meniere's disease: an evidence based approach to assessment and management. *Int J Clin Pract* 2012; **66**: 166-170 [PMID: 22257041 DOI: 10.1111/j.1742-1241.2011.02842.x]

69 **Ihler F**, Bertlich M, Sharaf K, Strieth S, Strupp M, Canis M. Betahistine exerts a dose-dependent effect on cochlear stria vascularis blood flow in guinea pigs in vivo. *PLoS One* 2012; **7**: e39086 [PMID: 22745706 DOI: 10.1371/journal.pone.0039086]

70 **Bertrand RA**. Long-term evaluation of the treatment of Menière's disease with betahistine HCl. *Adv Otorhinolaryngol* 1982; **28**: 104-110 [PMID: 7113814]

71 **Oosterveld WJ**. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. *J Laryngol Otol* 1984; **98**: 37-41 [PMID: 6363584 DOI: 10.1017/S0022215100146158]

72 **Fischer AJEM**, VanElferen LWM. Betahistine in the treatment of paroxysmal attacks of vertigo: a double blind trial. *J Drug Ther Res* 1985; **10**: 9

73 **Oosterveld WJ**, Blijleven W, Van Elferen LWM. Betahistine versus placebo in paroxysmal vertigo, a double blind trial. *J Drug Ther Res* 1989; **14**: 122-126

74 **Fraysse B**, Bebear JP, Dubreuil C, Berges C, Dauman R. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Menière's disease. *Acta Otolaryngol Suppl* 1991; **490**: 1-10 [PMID: 1763646]

75 **Hommes OR**. A study of the efficacy of betahistine in Méniére's syndrome. *Acta Otolaryngol Suppl* 1972; **305**: 70-79 [PMID: 4353751 DOI: 10.3109/00016487209122699]

76 **Weintraub J**, Arenberg IK, Spector GJ, Stroud MH. The efficacy of "conservative" medical regimens on the rate of hearing losses in Meniere's syndrome: a retrospective computerized statistical analysis. *Laryngoscope* 1976; **86**: 1391-1396 [PMID: 785131]

77 **James AL**, Burton MJ. Betahistine for Menière's disease or syndrome. *Cochrane Database Syst Rev* 2001; **(1)**: CD001873 [PMID: 11279734 DOI: 10.1002/14651858.CD001873]

78 **Tassinari M**, Mandrioli D, Gaggioli N, Roberti di Sarsina P. Ménière's disease treatment: a patient-centered systematic review. *Audiol Neurootol* 2015; **20**: 153-165 [PMID: 25832807 DOI: 10.1159/000375393]

79 **Jeck-Thole S**, Wagner W. Betahistine: a retrospective synopsis of safety data. *Drug Saf* 2006; **29**: 1049-1059 [PMID: 17061910 DOI: 10.2165/00002018-200629110-00004]

80 **White JP**, Mills J, Eiser NM. Comparison of the effects of histamine H1- and H2-receptor agonists on large and small airways in normal and asthmatic subjects. *Br J Dis Chest* 1987; **81**: 155-169 [PMID: 2958072 DOI: 10.1016/0007-0971(87)90134-3]

81 **Betts T**, Harris D, Gadd E. The effects of two anti-vertigo drugs (betahistine and prochlorperazine) on driving skills. *Br J Clin Pharmacol* 1991; **32**: 455-458 [PMID: 1958439 DOI: 10.1111/j.1365-2125.1991.tb03930.x]

82 **Zorzela L**, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, Loke Y, Vohra S. Quality of reporting in systematic reviews of adverse events: systematic review. *BMJ* 2014; **348**: f7668 [PMID: 24401468 DOI: 10.1136/bmj.f7668]

83 **Norris JW**. Steroids may have a role in stroke therapy. *Stroke* 2004; **35**: 228-229 [PMID: 14684781 DOI: 10.1161/01.STR.0000105930.29558.DB]

84 **Pondugula SR**, Sanneman JD, Wangemann P, Milhaud PG, Marcus DC. Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel. *Am J Physiol Renal Physiol* 2004; **286**: F1127-F1135 [PMID: 14996671 DOI: 10.1152/ajprenal.00387.2003]

85 **Garduño-Anaya MA**, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. *Otolaryngol Head Neck Surg* 2005; **133**: 285-294 [PMID: 16087029]

86 **Boleas-Aguirre MS**, Lin FR, Della Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. *Otol Neurotol* 2008; **29**: 33-38 [PMID: 18199956 DOI: 10.1097/mao.0b013e31815dbafc]

87 **Syed MI**, Ilan O, Nassar J, Rutka JA. Intratympanic therapy in Meniere's syndrome or disease: up to date evidence for clinical practise. *Clin Otolaryngol* 2015 [PMID: 25916787 DOI: 10.1111/coa.12449]

88 **Lyford-Pike S**, Vogelheim C, Chu E, Della Santina CC, Carey JP. Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration. *J Assoc Res Otolaryngol* 2007; **8**: 497-508 [PMID: 17899270 DOI: 10.1007/s10162-007-0093-8]

89 **Ohmori H**. Mechano-electrical transduction currents in isolated vestibular hair cells of the chick. *J Physiol* 1985; **359**: 189-217 [PMID: 2582113 DOI: 10.1113/jphysiol.1985.sp015581]

90 **Waguespack JR**, Ricci AJ. Aminoglycoside ototoxicity: permeant drugs cause permanent hair cell loss. *J Physiol* 2005; **567**: 359-360 [PMID: 16037084 DOI: 10.1113/jphysiol.2005.094474]

91 **Williams SE**, Zenner HP, Schacht J. Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. *Hear Res* 1987; **30**: 11-18 [PMID: 3680049 DOI: 10.1016/0378-5955(87)90177-8]

92 **Pullens B**, van Benthem PP. Intratympanic gentamicin for Ménière's disease or syndrome. *Cochrane Database Syst Rev* 2011; **(3)**: CD008234 [PMID: 21412917 DOI: 10.1002/14651858.CD008234.pub2]

93 **Postema RJ**, Kingma CM, Wit HP, Albers FW, Van Der Laan BF. Intratympanic gentamicin therapy for control of vertigo in unilateral Menire's disease: a prospective, double-blind, randomized, placebo-controlled trial. *Acta Otolaryngol* 2008; **128**: 876-880 [PMID: 18607963 DOI: 10.1080/00016480701762458]

94 **Casani AP**, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I. Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. *Otolaryngol Head Neck Surg* 2012; **146**: 430-437 [PMID: 22101095 DOI: 10.1177/0194599811429432]

95 **Nguyen KD**, Minor LB, Della Santina CC, Carey JP. Time course of repeated intratympanic gentamicin for Ménière's disease. *Laryngoscope* 2009; **119**: 792-798 [PMID: 19213044 DOI: 10.1002/lary.20055]

96 **Crane BT**, Minor LB, Della Santina CC, Carey JP. Middle ear exploration in patients with Ménière's disease who have failed outpatient intratympanic gentamicin therapy. *Otol Neurotol* 2009; **30**: 619-624 [PMID: 19503016 DOI: 10.1097/MAO.0b013e3181a66d2b]

97 **Carey JP**, Minor LB, Peng GC, Della Santina CC, Cremer PD, Haslwanter T. Changes in the three-dimensional angular vestibulo-ocular reflex following intratympanic gentamicin for Ménière's disease. *J Assoc Res Otolaryngol* 2002; **3**: 430-443 [PMID: 12486598]

98 **Wu IC**, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. *Laryngoscope* 2003; **113**: 815-820 [PMID: 12792316]

99 **Casani AP**, Cerchiai N, Navari E, Dallan I, Piaggi P, Sellari-Franceschini S. Intratympanic gentamicin for Meniere's disease: short- and long-term follow-up of two regimens of treatment. *Otolaryngol Head Neck Surg* 2014; **150**: 847-852 [PMID: 24477826 DOI: 10.1177/0194599813520398]

100 **Densert O**, Ingelstedt S, Ivarsson A, Pedersen K. Immediate restoration of basal sensorineural hearing (Mb Meniere) using a pressure chamber. *Acta Otolaryngol* 1975; **80**: 93-100 [PMID: 1166785 DOI: 10.3109/00016487509121306]

101 **Ahsan SF**, Standring R, Wang Y. Systematic review and meta-analysis of Meniett therapy for Meniere's disease. *Laryngoscope* 2015; **125**: 203-208 [PMID: 24913022 DOI: 10.1002/lary.24773]

102 **van Sonsbeek S**, Pullens B, van Benthem PP. Positive pressure therapy for Ménière's disease or syndrome. *Cochrane Database Syst Rev* 2015; **3**: CD008419 [PMID: 25756795 DOI: 10.1002/14651858.CD008419.pub2]

103 **Satoh H**, Firestein GS, Billings PB, Harris JP, Keithley EM. Proinflammatory cytokine expression in the endolymphatic sac during inner ear inflammation. *J Assoc Res Otolaryngol* 2003; **4**: 139-147 [PMID: 12943369 DOI: 10.1007/s10162-002-3025-7]

104 **Brinson GM**, Chen DA, Arriaga MA. Endolymphatic mastoid shunt versus endolymphatic sac decompression for Ménière's disease. *Otolaryngol Head Neck Surg* 2007; **136**: 415-421 [PMID: 17321870 DOI: 10.1016/j.otohns.2006.08.031]

105 **Brackmann DE**, Nissen RL. Menière's disease: results of treatment with the endolymphatic subarachnoid shunt compared with the endolymphatic mastoid shunt. *Am J Otol* 1987; **8**: 275-282 [PMID: 3631232]

106 **Chung JW**, Fayad J, Linthicum F, Ishiyama A, Merchant SN. Histopathology after endolymphatic sac surgery for Ménière's syndrome. *Otol Neurotol* 2011; **32**: 660-664 [PMID: 21436748 DOI: 10.1097/MAO.0b013e31821553ce]

107 **Ghossaini SN**, Wazen JJ. An update on the surgical treatment of Ménière's diseases. *J Am Acad Audiol* 2006; **17**: 38-44 [PMID: 16640059 DOI: 10.3766/jaaa.17.1.5]

108 **Paparella MM**, Fina M. Endolymphatic sac enhancement: reversal of pathogenesis. *Otolaryngol Clin North Am* 2002; **35**: 621-637 [PMID: 12486844 DOI: 10.1016/S0030-6665(02)00022-1]

109 **Huang TS**. Endolymphatic sac surgery for Meniere's disease: experience with over 3000 cases. *Otolaryngol Clin North Am* 2002; **35**: 591-606 [PMID: 12486842 DOI: 10.1016/S0030-6665(02)00027-0]

110 **Goldenberg RA**, Justus MA. Endolymphatic mastoid shunt for treatment of Meniere's disease: a five year study. *Laryngoscope* 1983; **93**: 1425-1429 [PMID: 6633114]

111 **Monsell EM**, Wiet RJ. Endolymphatic sac surgery: methods of study and results. *Am J Otol* 1988; **9**: 396-402 [PMID: 3144176]

112 **Huang TS**, Lin CC. A further critical assessment of the efficacy of endolymphatic sac surgery. *Acta Otolaryngol Suppl* 1995; **520** Pt 2: 263-269 [PMID: 8749135 DOI: 10.3109/00016489509125244]

113 **Pullens B**, Verschuur HP, van Benthem PP. Surgery for Ménière's disease. *Cochrane Database Syst Rev* 2013; **2**: CD005395 [PMID: 23450562 DOI: 10.1002/14651858.CD005395.pub3]

114 **Paparella MM**, Sajjadi H. Endolymphatic sac revision for recurrent Menière's disease. *Am J Otol* 1988; **9**: 441-447 [PMID: 3232713]

115 **Huang TS**, Lin CC. Revision endolymphatic sac surgery for recurrent Meniére's disease. *Acta Otolaryngol Suppl* 1991; **485**: 131-144 [PMID: 1843165 DOI: 10.3109/00016489109128053]

116 **Huang TS**, Lin CC. Endolymphatic sac ballooning surgery for Menière's disease. *Ann Otol Rhinol Laryngol* 1994; **103**: 389-394 [PMID: 8179256 DOI: 10.1177/000348949410300509]

117 **Huang TS**. Topical mitomycin C and cephalosporin in endolymphatic sac surgery. *Laryngoscope* 2002; **112**: 243-247 [PMID: 11889378 DOI: 10.1097/00005537-200202000-00009]

118 **Paparella MM**, Sajjadi H. Endolymphatic sac enhancement. Principles of diagnosis and treatment. *Am J Otol* 1987; **8**: 294-300 [PMID: 3631235]

119 **Silverstein H**, Norrell H, Rosenberg S. The resurrection of vestibular neurectomy: a 10-year experience with 115 cases. *J Neurosurg* 1990; **72**: 533-539 [PMID: 2319310 DOI: 10.3171/jns.1990.72.4.0533]

120 **Glasscock ME**, Thedinger BA, Cueva RA, Jackson CG. An analysis of the retrolabyrinthine vs. the retrosigmoid vestibular nerve section. *Otolaryngol Head Neck Surg* 1991; **104**: 88-95 [PMID: 1900636]

121 **McKenna MJ**, Nadol JB, Ojemann RG, Halpin C. Vestibular neurectomy: retrosigmoid-intracanalicular versus retrolabyrinthine approach. *Am J Otol* 1996; **17**: 253-258 [PMID: 8723957]

122 **Molony TB**. Decision making in vestibular neurectomy. *Am J Otol* 1996; **17**: 421-424 [PMID: 8817020]

123 **Rosenberg SI**. Vestibular surgery for Ménière's disease in the elderly: a review of techniques and indications. *Ear Nose Throat J* 1999; **78**: 443-446 [PMID: 10388195]

124 **Silverstein H**, Jackson LE. Vestibular nerve section. *Otolaryngol Clin North Am* 2002; **35**: 655-673 [PMID: 12486846 DOI: 10.1016/S0030-6665(02)00024-5]

125 **Rosenberg S**, Silverstein H, Norrell H, White D. Auditory and vestibular function after vestibular neurectomy. *Otolaryngol Head Neck Surg* 1991; **104**: 139-140 [PMID: 1900616]

126 **Benecke JE**, Tubergen LB, Miyamoto RT. Transmastoid labyrinthectomy. *Am J Otol* 1986; **7**: 41-43 [PMID: 3484907]

127 **Levine SC**, Glasscock M, McKennan KX. Long-term results of labyrinthectomy. *Laryngoscope* 1990; **100**: 125-127 [PMID: 2299951 DOI: 10.1288/00005537-199002000-00003]

128 **Graham MD**, Colton JJ. Transmastoid labyrinthectomy indications. Technique and early postoperative results. *Laryngoscope* 1980; **90**: 1253-1262 [PMID: 7401826 DOI: 10.1288/00005537-198008000-00001]

**P-Reviewer:** Algin O, Beltowski J **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Table 1 1995 American Academy of Otolaryngology-Head and Neck Surgery diagnostic criteria for Meniere’s disease**

|  |  |
| --- | --- |
| Certain | Definite Meniere’s + histological confirmation |
| Definite | ≥ 2 definitive spontaneous vertigo episodes ≥ 20 min+ all criteria in Probable Meniere’s disease |
| Probable | 1 definite episode of vertigoaudiometric hearing loss on ≥ 1 occasionAural fullness or tinnitus in the affected earOther causes exclude |
| Possible | Episodic vertigo of Meniere’s type with no documented hearing loss orFluctuating or fixed SNHL with disequilibrium without definitive vertigo episodesOther causes excluded |

**Table 2 New proposed diagnostic criteria for Meniere’s disease**

**Definite** MD

1 Two or more spontaneous episodes of vertigo, each lasting 20 min to 12 h

2 Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo

3 Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear

4 Not better accounted for by another vestibular diagnosis

**Probable** MD

1 Two or more episodes of vertigo or dizziness, each lasting 20 min to 24 h

2 Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear

3 Not better accounted for by another vestibular diagnosis